Citius Pharmaceuticals, Inc. (CTXR)
CTXR moved a median of -1.42% 30 minutes after news, and -2.02% by the close. How CTXR actually reacts to news — the realized, point-in-time move the market made, measured across 192 labeled events over the last three years with zero look-ahead.
CTXR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.56% | 40% | 192 |
| 30-min | -1.42% | 30% | 192 |
| 60-min | -1.30% | 32% | 192 |
| to close | -2.02% | 34% | 192 |
| Middle 50% of CTXR reactions | -3.75% to +0.85% |
|---|---|
| Median reaction (30-min) | -1.42% |
| Measured reactions | 192 |
Half of all Citius Pharmaceuticals, Inc. news events land between -3.75% and +0.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CTXR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CTXR's baseline. Nothing else.
Recent CTXR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Citius Pharmaceuticals to Participate in October 2026 Investor Conferences | Press release | PR Newswire | +0.02% | +0.57% | |
| Citius Pharmaceuticals to Participate in September 2026 Investor Conferences | Press release | PR Newswire | +2.63% | +2.99% | |
| Form 8-K Citius Pharmaceuticals, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | -5.67% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -3.52% | -9.65% | |
| Form 10-Q Citius Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.52% | -9.65% | |
| Form 8-K Citius Pharmaceuticals, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.52% | -9.65% | |
| Form 8-K Citius Pharmaceuticals, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +3.46% | +21.07% | |
| Form EFFECT Citius Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -1.96% | -1.91% | |
| Form 8-K Citius Pharmaceuticals, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -2.11% | -7.74% | |
| Form S-3 Citius Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | -3.58% | -0.99% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -10.95% | -7.54% | |
| Form 10-Q Citius Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -10.95% | -7.54% | |
| Form 8-K Citius Pharmaceuticals, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -10.95% | -7.54% | |
| Form 8-K Citius Pharmaceuticals, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -0.75% | |
| Form 8-K Citius Pharmaceuticals, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | +7.08% | |
| Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -8.97% | -1.28% | |
| Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -1.03% | -6.62% | |
| Form 8-K Citius Pharmaceuticals, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -6.62% | |
| Form 8-K Citius Pharmaceuticals, For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | -1.95% | -7.51% | |
| Form 8-K Citius Pharmaceuticals, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -5.96% | -6.32% | |
| Form 8-K Citius Pharmaceuticals, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +2.57% | +3.44% | |
| Form 8-K Citius Pharmaceuticals, For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | +6.07% | |
| Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program | Press release | PR Newswire | -0.96% | +12.37% | |
| Form ARS Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form ARS | SEC EDGAR | -0.96% | +12.37% | |
| Form DEF 14A Citius Pharmaceuticals, For: Apr 06 | SEC filing · Form DEF | SEC EDGAR | -0.96% | +12.37% | |
| Form DEFA14A Citius Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.96% | +12.37% | |
| Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ | Press release | PR Newswire | +0.01% | -8.90% | |
| Form 10-Q Citius Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.01% | -8.90% | |
| Form 8-K Citius Pharmaceuticals, For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -8.90% | |
| Form 10-K/A Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | SEC EDGAR | -3.55% | -3.75% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | -10.16% | -32.15% | |
| Form 10-K Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | SEC EDGAR | -10.16% | -32.15% | |
| Form 8-K Citius Pharmaceuticals, For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | -10.16% | -32.15% | |
| Form 8-K Citius Pharmaceuticals, For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -4.29% | -10.64% | |
| Form 8-K Citius Pharmaceuticals, For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -10.41% | -8.08% | |
| Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -1.21% | +1.21% | |
| Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | +0.89% | -7.10% | |
| Form 8-K Citius Pharmaceuticals, For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -7.10% | |
| Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences | Press release | PR Newswire | +1.91% | +15.29% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update | Press release | PR Newswire | +2.34% | +2.40% | |
| Form 10-Q Citius Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.34% | +2.40% | |
| Form 8-K Citius Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +2.34% | +2.40% | |
| Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | PR Newswire | -5.63% | -9.15% | |
| Form 8-K Citius Pharmaceuticals, For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -2.99% | -9.23% | |
| Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | +1.02% | -6.12% | |
| Form 8-K Citius Pharmaceuticals, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | -6.12% | |
| Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -3.54% | +6.00% | |
| Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | Press release | PR Newswire | -1.10% | +50.55% | |
| Form 8-K Citius Pharmaceuticals, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -3.54% | +6.00% | |
| Form 8-K Citius Pharmaceuticals, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -3.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CTXR section they belong to.
Where else CTXR is measured.
CTXR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | 193 | 0.00% | 42% |
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Citius Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CTXR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 192 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 30% of CTXR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CTXR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.